Aripiprazole lauroxil (Aristada) vs Brexpiprazole (Rexulti)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline

Aripiprazole lauroxil (Aristada)

Marketed by Alkermes plc

Approved in Schizophreniasmall molecule
Reliable signal

NCT01469039 · Phase 3 · completed

The trial was randomized, quadruple-blinded, and placebo-controlled, with 623 participants assigned to aripiprazole lauroxil 441 mg, 882 mg, or placebo. Its primary clinical symptom endpoint, change in PANSS total score at day 85, was significantly better with both active doses than with placebo (p<0.001 for each comparison).

Reported efficacy

The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39) (met)

Result source: NCT01469039

Brexpiprazole (Rexulti)

Marketed by Otsuka Holdings and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT01393613 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial in 674 patients with acute schizophrenia, using a validated symptom-severity scale (PANSS) as the primary measure. The pooled comparison of the two higher doses against placebo reached statistical significance (p=0.0093), and the 4 mg dose was significant on its own (p=0.0022), but the 1 mg and 2 mg doses individually did not separate from placebo, so the result was only partially met.

Next expected readout: August 2027 · NCT07742280 (registry estimate)

Reported efficacy

Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score: Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014 (met)

Result source: NCT03198078

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAripiprazole lauroxil (Aristada)Brexpiprazole (Rexulti)
PANSS total, change-21.8 vs -9.8−12 vs placebo882 mg · wk 12.14 · n 204NCT01469039
1 other result
  • -20.9 vs -9.8 441 mg · wk 12.14 · n 196 · Phase 3 · primary NCT01469039
-16.6 vs -13.5−3.1 vs placebo2 mg · wk 6 · n 179NCT01393613
71 other results
  • -20.7 vs -12.0 2 mg · wk 6 · n 132 · Phase 3 · primary NCT01396421
  • -14.9 vs -7.6 2 mg · wk 6 · n 113 · Phase 2/3 · primary NCT01451164
  • -14.1 vs -11.9 2 mg · wk 5 · n 179 · Phase 3 · primary NCT01393613
  • -14.0 vs -6.6 2 mg · wk 5 · n 113 · Phase 2/3 · primary NCT01451164
  • -13.1 vs -11.1 2 mg · wk 4 · n 179 · Phase 3 · primary NCT01393613
  • -12.3 vs -5.7 2 mg · wk 4 · n 113 · Phase 2/3 · primary NCT01451164
  • -10.7 vs -8.9 2 mg · wk 3 · n 179 · Phase 3 · primary NCT01393613
  • -11 vs -6 2 mg · wk 3 · n 113 · Phase 2/3 · primary NCT01451164
  • -8.7 vs -6.6 2 mg · wk 2 · n 179 · Phase 3 · primary NCT01393613
  • -7.9 vs -4.5 2 mg · wk 2 · n 113 · Phase 2/3 · primary NCT01451164
  • -4.3 vs -3.5 2 mg · wk 1 · n 179 · Phase 3 · primary NCT01393613
  • -4.6 vs -3.1 2 mg · wk 1 · n 113 · Phase 2/3 · primary NCT01451164
  • -20 vs -13.5 4 mg · wk 6 · n 181 · Phase 3 · primary NCT01393613
  • -19.6 vs -12.0 4 mg · wk 6 · n 134 · Phase 3 · primary NCT01396421
  • -11.5 vs -7.6 4 mg · wk 6 · n 109 · Phase 2/3 · primary NCT01451164
  • -17.3 vs -11.9 4 mg · wk 5 · n 181 · Phase 3 · primary NCT01393613
  • -11.1 vs -6.6 4 mg · wk 5 · n 109 · Phase 2/3 · primary NCT01451164
  • -15.6 vs -11.1 4 mg · wk 4 · n 181 · Phase 3 · primary NCT01393613
  • -11.2 vs -5.7 4 mg · wk 4 · n 109 · Phase 2/3 · primary NCT01451164
  • -12.6 vs -8.9 4 mg · wk 3 · n 181 · Phase 3 · primary NCT01393613
  • -9.4 vs -6 4 mg · wk 3 · n 109 · Phase 2/3 · primary NCT01451164
  • -8.4 vs -6.6 4 mg · wk 2 · n 181 · Phase 3 · primary NCT01393613
  • -6.8 vs -4.5 4 mg · wk 2 · n 109 · Phase 2/3 · primary NCT01451164
  • -5.6 vs -3.5 4 mg · wk 1 · n 181 · Phase 3 · primary NCT01393613
  • -3.4 vs -3.1 4 mg · wk 1 · n 109 · Phase 2/3 · primary NCT01451164
  • -16.9 vs -13.5 1 mg · wk 6 · n 117 · Phase 3 · primary NCT01393613
  • -8.3 vs -7.6 1 mg · wk 6 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.5 vs -11.9 1 mg · wk 5 · n 117 · Phase 3 · primary NCT01393613
  • -8.1 vs -6.6 1 mg · wk 5 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.0 vs -11.1 1 mg · wk 4 · n 117 · Phase 3 · primary NCT01393613
  • -8.4 vs -5.7 1 mg · wk 4 · n 112 · Phase 2/3 · primary NCT01451164
  • -11.6 vs -8.9 1 mg · wk 3 · n 117 · Phase 3 · primary NCT01393613
  • -6.9 vs -6 1 mg · wk 3 · n 112 · Phase 2/3 · primary NCT01451164
  • -7.6 vs -6.6 1 mg · wk 2 · n 117 · Phase 3 · primary NCT01393613
  • -5.1 vs -4.5 1 mg · wk 2 · n 112 · Phase 2/3 · primary NCT01451164
  • -3.3 vs -3.5 1 mg · wk 1 · n 117 · Phase 3 · primary NCT01393613
  • -2.7 vs -3.1 1 mg · wk 1 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.9 vs -12.0 0.25 mg · wk 6 · n 62 · Phase 3 · primary NCT01396421
  • -22.8 vs -17.4 wk 6 · n 110 · Phase 3 · primary NCT03198078
  • -20 vs -15.9 wk 6 · n 150 · Phase 3 · primary NCT01810380
  • -22.9 vs -19.4 wk 6 · n 64 · Phase 3 · primary NCT02054702
  • -17.9 vs -10.8 2 mg · wk 5 · n 180 · Phase 3 · secondary NCT01396421
  • -14.1 vs -8.9 2 mg · wk 4 · n 180 · Phase 3 · secondary NCT01396421
  • -11.1 vs -7.6 2 mg · wk 3 · n 180 · Phase 3 · secondary NCT01396421
  • -8.9 vs -5.1 2 mg · wk 2 · n 180 · Phase 3 · secondary NCT01396421
  • -4.9 vs -2.9 2 mg · wk 1 · n 180 · Phase 3 · secondary NCT01396421
  • -18.6 vs -10.8 4 mg · wk 5 · n 178 · Phase 3 · secondary NCT01396421
  • -16.5 vs -8.9 4 mg · wk 4 · n 178 · Phase 3 · secondary NCT01396421
  • -12.8 vs -7.6 4 mg · wk 3 · n 178 · Phase 3 · secondary NCT01396421
  • -9.5 vs -5.1 4 mg · wk 2 · n 178 · Phase 3 · secondary NCT01396421
  • -4.4 vs -2.9 4 mg · wk 1 · n 178 · Phase 3 · secondary NCT01396421
  • -11.9 vs -10.8 0.25 mg · wk 5 · n 87 · Phase 3 · secondary NCT01396421
  • -8.9 vs -8.9 0.25 mg · wk 4 · n 87 · Phase 3 · secondary NCT01396421
  • -5.7 vs -7.6 0.25 mg · wk 3 · n 87 · Phase 3 · secondary NCT01396421
  • -3.3 vs -5.1 0.25 mg · wk 2 · n 87 · Phase 3 · secondary NCT01396421
  • -2.5 vs -2.9 0.25 mg · wk 1 · n 87 · Phase 3 · secondary NCT01396421
  • 0.6 vs 6.9 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 3.3 vs 11.2 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • -2.7 vs 3.3 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 2.5 vs 10.5 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • -1.9 vs 2.9 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 1.6 vs 9.2 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 0.8 vs 6.2 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • 1.6 vs 6.6 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • 0.8 vs 4.1 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • 0.5 vs 3.6 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -9.8 vs -14.4 0.25 mg · wk 6 · n 41 · Phase 2 · primary NCT00905307
  • -18.7 vs -14.4 Low-dose · wk 6 · n 88 · Phase 2 · primary NCT00905307
  • -16.2 vs -14.4 Mid-dose · wk 6 · n 90 · Phase 2 · primary NCT00905307
  • -18.3 vs -14.4 High-dose · wk 6 · n 92 · Phase 2 · primary NCT00905307
  • -3.7 vs -0.3 wk 12 · n 21 · Phase 4 · secondary NCT03526354
CGI-S, change-0.5 vs -0.9+0.4 vs placebo441-441 mg · wk 52 · n 80NCT01626456
2 other results
  • -0.3 vs -0.9 882-882 mg · wk 52 · n 94 · Phase 3 · secondary NCT01626456
  • -0.2 vs -0.9 wk 52 · n 233 · Phase 3 · secondary NCT01626456
-1.0 vs -0.8−0.2 vs placebo2 mg · wk 6 · n 180NCT01393613
71 other results
  • -1.1 vs -0.8 2 mg · wk 6 · n 124 · Phase 3 · secondary NCT01396421
  • -0.8 vs -0.6 2 mg · wk 6 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.7 2 mg · wk 5 · n 180 · Phase 3 · secondary NCT01393613
  • -1.0 vs -0.7 2 mg · wk 5 · n 181 · Phase 3 · secondary NCT01396421
  • -0.8 vs -0.5 2 mg · wk 5 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.6 2 mg · wk 4 · n 180 · Phase 3 · secondary NCT01393613
  • -0.7 vs -0.5 2 mg · wk 4 · n 181 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.4 2 mg · wk 4 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.6 vs -0.4 2 mg · wk 3 · n 180 · Phase 3 · secondary NCT01393613
  • -0.6 vs -0.5 2 mg · wk 3 · n 181 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 2 mg · wk 3 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.4 vs -0.4 2 mg · wk 2 · n 180 · Phase 3 · secondary NCT01393613
  • -0.4 vs -0.3 2 mg · wk 2 · n 181 · Phase 3 · secondary NCT01396421
  • -0.4 vs -0.3 2 mg · wk 2 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.2 vs -0.1 2 mg · wk 1 · n 180 · Phase 3 · secondary NCT01393613
  • -0.2 vs -0.1 2 mg · wk 1 · n 181 · Phase 3 · secondary NCT01396421
  • -0.2 vs -0.1 2 mg · wk 1 · n 113 · Phase 2/3 · secondary NCT01451164
  • -1.2 vs -0.8 4 mg · wk 6 · n 183 · Phase 3 · secondary NCT01393613
  • -1.2 vs -0.8 4 mg · wk 6 · n 121 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.6 4 mg · wk 6 · n 109 · Phase 2/3 · secondary NCT01451164
  • -1.0 vs -0.7 4 mg · wk 5 · n 183 · Phase 3 · secondary NCT01393613
  • -1.1 vs -0.7 4 mg · wk 5 · n 178 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.5 4 mg · wk 5 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.6 4 mg · wk 4 · n 183 · Phase 3 · secondary NCT01393613
  • -1.0 vs -0.5 4 mg · wk 4 · n 178 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 4 mg · wk 4 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.4 4 mg · wk 3 · n 183 · Phase 3 · secondary NCT01393613
  • -0.7 vs -0.5 4 mg · wk 3 · n 178 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 4 mg · wk 3 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.4 vs -0.4 4 mg · wk 2 · n 183 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.3 4 mg · wk 2 · n 178 · Phase 3 · secondary NCT01396421
  • -0.3 vs -0.3 4 mg · wk 2 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.2 vs -0.1 4 mg · wk 1 · n 183 · Phase 3 · secondary NCT01393613
  • -0.2 vs -0.1 4 mg · wk 1 · n 178 · Phase 3 · secondary NCT01396421
  • -0.1 vs -0.1 4 mg · wk 1 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.9 vs -0.8 1 mg · wk 6 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.6 1 mg · wk 6 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.7 1 mg · wk 5 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.5 1 mg · wk 5 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.6 1 mg · wk 4 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.4 1 mg · wk 4 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.6 vs -0.4 1 mg · wk 3 · n 120 · Phase 3 · secondary NCT01393613
  • -0.4 vs -0.4 1 mg · wk 3 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.3 vs -0.4 1 mg · wk 2 · n 120 · Phase 3 · secondary NCT01393613
  • -0.3 vs -0.3 1 mg · wk 2 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.1 vs -0.1 1 mg · wk 1 · n 120 · Phase 3 · secondary NCT01393613
  • -0.1 vs -0.1 1 mg · wk 1 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.8 0.25 mg · wk 6 · n 56 · Phase 3 · secondary NCT01396421
  • -0.7 vs -0.7 0.25 mg · wk 5 · n 89 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.5 0.25 mg · wk 4 · n 89 · Phase 3 · secondary NCT01396421
  • -0.3 vs -0.5 0.25 mg · wk 3 · n 89 · Phase 3 · secondary NCT01396421
  • -0.2 vs -0.3 0.25 mg · wk 2 · n 89 · Phase 3 · secondary NCT01396421
  • -0.1 vs -0.1 0.25 mg · wk 1 · n 89 · Phase 3 · secondary NCT01396421
  • -0.2 vs 0.3 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 0.0 vs 0.6 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • -0.3 vs 0.3 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 0 vs 0.6 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • -0.2 vs 0.2 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.5 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.4 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.3 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -0.9 vs -0.8 wk 6 · n 110 · Phase 3 · secondary NCT03198078
  • -0.0 vs 0.3 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -0.1 vs 0.2 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -1.2 vs -0.9 wk 6 · n 150 · Phase 3 · secondary NCT01810380
  • -1.6 vs -1.3 wk 6 · n 64 · Phase 3 · secondary NCT02054702
  • -0.4 vs -0.8 0.25 mg · wk 6 · n 41 · Phase 2 · secondary NCT00905307
  • -1.0 vs -0.8 Low-dose · wk 6 · n 88 · Phase 2 · secondary NCT00905307
  • -0.9 vs -0.8 Mid-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
  • -1.1 vs -0.8 High-dose · wk 6 · n 92 · Phase 2 · secondary NCT00905307
  • -0.3 vs -0.1 wk 12 · n 21 · Phase 4 · secondary NCT03526354
PANSS response—Not reported38.5% vs 31.7%+6.8 vs placebo2 mg · wk 6 · n 179NCT01393613
8 other results
  • 49.7% vs 31.7% 4 mg · wk 6 · n 181 · Phase 3 · secondary NCT01393613
  • 43.6% vs 31.7% 1 mg · wk 6 · n 117 · Phase 3 · secondary NCT01393613
  • 43.6% vs 28.2% wk 6 · n 110 · Phase 3 · secondary NCT03198078
  • 48.7% vs 32.1% wk 6 · n 150 · Phase 3 · secondary NCT01810380
  • 40.5% vs 49.5% 0.25 mg · wk 6 · n 42 · Phase 2 · secondary NCT00905307
  • 57.3% vs 49.5% Low-dose · wk 6 · n 89 · Phase 2 · secondary NCT00905307
  • 46.7% vs 49.5% Mid-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
  • 51.6% vs 49.5% High-dose · wk 6 · n 93 · Phase 2 · secondary NCT00905307
PSP, change—Not reported10.5 vs 8.5+2 vs placebo2 mg · wk 6 · n 170NCT01393613
17 other results
  • 13.2 vs 10.3 2 mg · wk 6 · n 122 · Phase 3 · secondary NCT01396421
  • 6.8 vs 5.8 2 mg · wk 3 · n 170 · Phase 3 · secondary NCT01393613
  • 13.1 vs 8.5 4 mg · wk 6 · n 174 · Phase 3 · secondary NCT01393613
  • 12.7 vs 10.3 4 mg · wk 6 · n 121 · Phase 3 · secondary NCT01396421
  • 7.1 vs 5.8 4 mg · wk 3 · n 174 · Phase 3 · secondary NCT01393613
  • 11.7 vs 8.5 1 mg · wk 6 · n 105 · Phase 3 · secondary NCT01393613
  • 7.0 vs 5.8 1 mg · wk 3 · n 105 · Phase 3 · secondary NCT01393613
  • 11.8 vs 10.3 0.25 mg · wk 6 · n 55 · Phase 3 · secondary NCT01396421
  • 18.6 vs 12.6 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 15.1 vs 10.3 wk 52 · n 94 · Phase 3 · secondary NCT01668797
  • 18.9 vs 17.8 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 15.2 vs 11.4 wk 24 · n 94 · Phase 3 · secondary NCT01668797
  • 13 vs 9.4 wk 6 · n 133 · Phase 3 · secondary NCT01810380
  • 4.5 vs 7.6 0.25 mg · wk 6 · n 39 · Phase 2 · secondary NCT00905307
  • 11.4 vs 7.6 Low-dose · wk 6 · n 86 · Phase 2 · secondary NCT00905307
  • 10.7 vs 7.6 Mid-dose · wk 6 · n 84 · Phase 2 · secondary NCT00905307
  • 12.2 vs 7.6 High-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
Relapse (% of patients)—Not reported13.5% vs 38.5%−24.9 vs placebowk 52 · n 96NCT01668797

PANSS total, change

Aripiprazole lauroxil (Aristada)
-21.8 vs -9.8−12 vs placebo882 mg · wk 12.14 · n 204NCT01469039
1 other result
  • -20.9 vs -9.8 441 mg · wk 12.14 · n 196 · Phase 3 · primary NCT01469039
Brexpiprazole (Rexulti)
-16.6 vs -13.5−3.1 vs placebo2 mg · wk 6 · n 179NCT01393613
71 other results
  • -20.7 vs -12.0 2 mg · wk 6 · n 132 · Phase 3 · primary NCT01396421
  • -14.9 vs -7.6 2 mg · wk 6 · n 113 · Phase 2/3 · primary NCT01451164
  • -14.1 vs -11.9 2 mg · wk 5 · n 179 · Phase 3 · primary NCT01393613
  • -14.0 vs -6.6 2 mg · wk 5 · n 113 · Phase 2/3 · primary NCT01451164
  • -13.1 vs -11.1 2 mg · wk 4 · n 179 · Phase 3 · primary NCT01393613
  • -12.3 vs -5.7 2 mg · wk 4 · n 113 · Phase 2/3 · primary NCT01451164
  • -10.7 vs -8.9 2 mg · wk 3 · n 179 · Phase 3 · primary NCT01393613
  • -11 vs -6 2 mg · wk 3 · n 113 · Phase 2/3 · primary NCT01451164
  • -8.7 vs -6.6 2 mg · wk 2 · n 179 · Phase 3 · primary NCT01393613
  • -7.9 vs -4.5 2 mg · wk 2 · n 113 · Phase 2/3 · primary NCT01451164
  • -4.3 vs -3.5 2 mg · wk 1 · n 179 · Phase 3 · primary NCT01393613
  • -4.6 vs -3.1 2 mg · wk 1 · n 113 · Phase 2/3 · primary NCT01451164
  • -20 vs -13.5 4 mg · wk 6 · n 181 · Phase 3 · primary NCT01393613
  • -19.6 vs -12.0 4 mg · wk 6 · n 134 · Phase 3 · primary NCT01396421
  • -11.5 vs -7.6 4 mg · wk 6 · n 109 · Phase 2/3 · primary NCT01451164
  • -17.3 vs -11.9 4 mg · wk 5 · n 181 · Phase 3 · primary NCT01393613
  • -11.1 vs -6.6 4 mg · wk 5 · n 109 · Phase 2/3 · primary NCT01451164
  • -15.6 vs -11.1 4 mg · wk 4 · n 181 · Phase 3 · primary NCT01393613
  • -11.2 vs -5.7 4 mg · wk 4 · n 109 · Phase 2/3 · primary NCT01451164
  • -12.6 vs -8.9 4 mg · wk 3 · n 181 · Phase 3 · primary NCT01393613
  • -9.4 vs -6 4 mg · wk 3 · n 109 · Phase 2/3 · primary NCT01451164
  • -8.4 vs -6.6 4 mg · wk 2 · n 181 · Phase 3 · primary NCT01393613
  • -6.8 vs -4.5 4 mg · wk 2 · n 109 · Phase 2/3 · primary NCT01451164
  • -5.6 vs -3.5 4 mg · wk 1 · n 181 · Phase 3 · primary NCT01393613
  • -3.4 vs -3.1 4 mg · wk 1 · n 109 · Phase 2/3 · primary NCT01451164
  • -16.9 vs -13.5 1 mg · wk 6 · n 117 · Phase 3 · primary NCT01393613
  • -8.3 vs -7.6 1 mg · wk 6 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.5 vs -11.9 1 mg · wk 5 · n 117 · Phase 3 · primary NCT01393613
  • -8.1 vs -6.6 1 mg · wk 5 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.0 vs -11.1 1 mg · wk 4 · n 117 · Phase 3 · primary NCT01393613
  • -8.4 vs -5.7 1 mg · wk 4 · n 112 · Phase 2/3 · primary NCT01451164
  • -11.6 vs -8.9 1 mg · wk 3 · n 117 · Phase 3 · primary NCT01393613
  • -6.9 vs -6 1 mg · wk 3 · n 112 · Phase 2/3 · primary NCT01451164
  • -7.6 vs -6.6 1 mg · wk 2 · n 117 · Phase 3 · primary NCT01393613
  • -5.1 vs -4.5 1 mg · wk 2 · n 112 · Phase 2/3 · primary NCT01451164
  • -3.3 vs -3.5 1 mg · wk 1 · n 117 · Phase 3 · primary NCT01393613
  • -2.7 vs -3.1 1 mg · wk 1 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.9 vs -12.0 0.25 mg · wk 6 · n 62 · Phase 3 · primary NCT01396421
  • -22.8 vs -17.4 wk 6 · n 110 · Phase 3 · primary NCT03198078
  • -20 vs -15.9 wk 6 · n 150 · Phase 3 · primary NCT01810380
  • -22.9 vs -19.4 wk 6 · n 64 · Phase 3 · primary NCT02054702
  • -17.9 vs -10.8 2 mg · wk 5 · n 180 · Phase 3 · secondary NCT01396421
  • -14.1 vs -8.9 2 mg · wk 4 · n 180 · Phase 3 · secondary NCT01396421
  • -11.1 vs -7.6 2 mg · wk 3 · n 180 · Phase 3 · secondary NCT01396421
  • -8.9 vs -5.1 2 mg · wk 2 · n 180 · Phase 3 · secondary NCT01396421
  • -4.9 vs -2.9 2 mg · wk 1 · n 180 · Phase 3 · secondary NCT01396421
  • -18.6 vs -10.8 4 mg · wk 5 · n 178 · Phase 3 · secondary NCT01396421
  • -16.5 vs -8.9 4 mg · wk 4 · n 178 · Phase 3 · secondary NCT01396421
  • -12.8 vs -7.6 4 mg · wk 3 · n 178 · Phase 3 · secondary NCT01396421
  • -9.5 vs -5.1 4 mg · wk 2 · n 178 · Phase 3 · secondary NCT01396421
  • -4.4 vs -2.9 4 mg · wk 1 · n 178 · Phase 3 · secondary NCT01396421
  • -11.9 vs -10.8 0.25 mg · wk 5 · n 87 · Phase 3 · secondary NCT01396421
  • -8.9 vs -8.9 0.25 mg · wk 4 · n 87 · Phase 3 · secondary NCT01396421
  • -5.7 vs -7.6 0.25 mg · wk 3 · n 87 · Phase 3 · secondary NCT01396421
  • -3.3 vs -5.1 0.25 mg · wk 2 · n 87 · Phase 3 · secondary NCT01396421
  • -2.5 vs -2.9 0.25 mg · wk 1 · n 87 · Phase 3 · secondary NCT01396421
  • 0.6 vs 6.9 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 3.3 vs 11.2 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • -2.7 vs 3.3 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 2.5 vs 10.5 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • -1.9 vs 2.9 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 1.6 vs 9.2 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 0.8 vs 6.2 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • 1.6 vs 6.6 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • 0.8 vs 4.1 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • 0.5 vs 3.6 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -9.8 vs -14.4 0.25 mg · wk 6 · n 41 · Phase 2 · primary NCT00905307
  • -18.7 vs -14.4 Low-dose · wk 6 · n 88 · Phase 2 · primary NCT00905307
  • -16.2 vs -14.4 Mid-dose · wk 6 · n 90 · Phase 2 · primary NCT00905307
  • -18.3 vs -14.4 High-dose · wk 6 · n 92 · Phase 2 · primary NCT00905307
  • -3.7 vs -0.3 wk 12 · n 21 · Phase 4 · secondary NCT03526354

CGI-S, change

Aripiprazole lauroxil (Aristada)
-0.5 vs -0.9+0.4 vs placebo441-441 mg · wk 52 · n 80NCT01626456
2 other results
  • -0.3 vs -0.9 882-882 mg · wk 52 · n 94 · Phase 3 · secondary NCT01626456
  • -0.2 vs -0.9 wk 52 · n 233 · Phase 3 · secondary NCT01626456
Brexpiprazole (Rexulti)
-1.0 vs -0.8−0.2 vs placebo2 mg · wk 6 · n 180NCT01393613
71 other results
  • -1.1 vs -0.8 2 mg · wk 6 · n 124 · Phase 3 · secondary NCT01396421
  • -0.8 vs -0.6 2 mg · wk 6 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.7 2 mg · wk 5 · n 180 · Phase 3 · secondary NCT01393613
  • -1.0 vs -0.7 2 mg · wk 5 · n 181 · Phase 3 · secondary NCT01396421
  • -0.8 vs -0.5 2 mg · wk 5 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.6 2 mg · wk 4 · n 180 · Phase 3 · secondary NCT01393613
  • -0.7 vs -0.5 2 mg · wk 4 · n 181 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.4 2 mg · wk 4 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.6 vs -0.4 2 mg · wk 3 · n 180 · Phase 3 · secondary NCT01393613
  • -0.6 vs -0.5 2 mg · wk 3 · n 181 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 2 mg · wk 3 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.4 vs -0.4 2 mg · wk 2 · n 180 · Phase 3 · secondary NCT01393613
  • -0.4 vs -0.3 2 mg · wk 2 · n 181 · Phase 3 · secondary NCT01396421
  • -0.4 vs -0.3 2 mg · wk 2 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.2 vs -0.1 2 mg · wk 1 · n 180 · Phase 3 · secondary NCT01393613
  • -0.2 vs -0.1 2 mg · wk 1 · n 181 · Phase 3 · secondary NCT01396421
  • -0.2 vs -0.1 2 mg · wk 1 · n 113 · Phase 2/3 · secondary NCT01451164
  • -1.2 vs -0.8 4 mg · wk 6 · n 183 · Phase 3 · secondary NCT01393613
  • -1.2 vs -0.8 4 mg · wk 6 · n 121 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.6 4 mg · wk 6 · n 109 · Phase 2/3 · secondary NCT01451164
  • -1.0 vs -0.7 4 mg · wk 5 · n 183 · Phase 3 · secondary NCT01393613
  • -1.1 vs -0.7 4 mg · wk 5 · n 178 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.5 4 mg · wk 5 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.6 4 mg · wk 4 · n 183 · Phase 3 · secondary NCT01393613
  • -1.0 vs -0.5 4 mg · wk 4 · n 178 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 4 mg · wk 4 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.4 4 mg · wk 3 · n 183 · Phase 3 · secondary NCT01393613
  • -0.7 vs -0.5 4 mg · wk 3 · n 178 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 4 mg · wk 3 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.4 vs -0.4 4 mg · wk 2 · n 183 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.3 4 mg · wk 2 · n 178 · Phase 3 · secondary NCT01396421
  • -0.3 vs -0.3 4 mg · wk 2 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.2 vs -0.1 4 mg · wk 1 · n 183 · Phase 3 · secondary NCT01393613
  • -0.2 vs -0.1 4 mg · wk 1 · n 178 · Phase 3 · secondary NCT01396421
  • -0.1 vs -0.1 4 mg · wk 1 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.9 vs -0.8 1 mg · wk 6 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.6 1 mg · wk 6 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.7 1 mg · wk 5 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.5 1 mg · wk 5 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.6 1 mg · wk 4 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.4 1 mg · wk 4 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.6 vs -0.4 1 mg · wk 3 · n 120 · Phase 3 · secondary NCT01393613
  • -0.4 vs -0.4 1 mg · wk 3 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.3 vs -0.4 1 mg · wk 2 · n 120 · Phase 3 · secondary NCT01393613
  • -0.3 vs -0.3 1 mg · wk 2 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.1 vs -0.1 1 mg · wk 1 · n 120 · Phase 3 · secondary NCT01393613
  • -0.1 vs -0.1 1 mg · wk 1 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.8 0.25 mg · wk 6 · n 56 · Phase 3 · secondary NCT01396421
  • -0.7 vs -0.7 0.25 mg · wk 5 · n 89 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.5 0.25 mg · wk 4 · n 89 · Phase 3 · secondary NCT01396421
  • -0.3 vs -0.5 0.25 mg · wk 3 · n 89 · Phase 3 · secondary NCT01396421
  • -0.2 vs -0.3 0.25 mg · wk 2 · n 89 · Phase 3 · secondary NCT01396421
  • -0.1 vs -0.1 0.25 mg · wk 1 · n 89 · Phase 3 · secondary NCT01396421
  • -0.2 vs 0.3 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 0.0 vs 0.6 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • -0.3 vs 0.3 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 0 vs 0.6 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • -0.2 vs 0.2 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.5 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.4 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.3 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -0.9 vs -0.8 wk 6 · n 110 · Phase 3 · secondary NCT03198078
  • -0.0 vs 0.3 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -0.1 vs 0.2 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -1.2 vs -0.9 wk 6 · n 150 · Phase 3 · secondary NCT01810380
  • -1.6 vs -1.3 wk 6 · n 64 · Phase 3 · secondary NCT02054702
  • -0.4 vs -0.8 0.25 mg · wk 6 · n 41 · Phase 2 · secondary NCT00905307
  • -1.0 vs -0.8 Low-dose · wk 6 · n 88 · Phase 2 · secondary NCT00905307
  • -0.9 vs -0.8 Mid-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
  • -1.1 vs -0.8 High-dose · wk 6 · n 92 · Phase 2 · secondary NCT00905307
  • -0.3 vs -0.1 wk 12 · n 21 · Phase 4 · secondary NCT03526354

PANSS response

Aripiprazole lauroxil (Aristada)
—Not reported
Brexpiprazole (Rexulti)
38.5% vs 31.7%+6.8 vs placebo2 mg · wk 6 · n 179NCT01393613
8 other results
  • 49.7% vs 31.7% 4 mg · wk 6 · n 181 · Phase 3 · secondary NCT01393613
  • 43.6% vs 31.7% 1 mg · wk 6 · n 117 · Phase 3 · secondary NCT01393613
  • 43.6% vs 28.2% wk 6 · n 110 · Phase 3 · secondary NCT03198078
  • 48.7% vs 32.1% wk 6 · n 150 · Phase 3 · secondary NCT01810380
  • 40.5% vs 49.5% 0.25 mg · wk 6 · n 42 · Phase 2 · secondary NCT00905307
  • 57.3% vs 49.5% Low-dose · wk 6 · n 89 · Phase 2 · secondary NCT00905307
  • 46.7% vs 49.5% Mid-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
  • 51.6% vs 49.5% High-dose · wk 6 · n 93 · Phase 2 · secondary NCT00905307

PSP, change

Aripiprazole lauroxil (Aristada)
—Not reported
Brexpiprazole (Rexulti)
10.5 vs 8.5+2 vs placebo2 mg · wk 6 · n 170NCT01393613
17 other results
  • 13.2 vs 10.3 2 mg · wk 6 · n 122 · Phase 3 · secondary NCT01396421
  • 6.8 vs 5.8 2 mg · wk 3 · n 170 · Phase 3 · secondary NCT01393613
  • 13.1 vs 8.5 4 mg · wk 6 · n 174 · Phase 3 · secondary NCT01393613
  • 12.7 vs 10.3 4 mg · wk 6 · n 121 · Phase 3 · secondary NCT01396421
  • 7.1 vs 5.8 4 mg · wk 3 · n 174 · Phase 3 · secondary NCT01393613
  • 11.7 vs 8.5 1 mg · wk 6 · n 105 · Phase 3 · secondary NCT01393613
  • 7.0 vs 5.8 1 mg · wk 3 · n 105 · Phase 3 · secondary NCT01393613
  • 11.8 vs 10.3 0.25 mg · wk 6 · n 55 · Phase 3 · secondary NCT01396421
  • 18.6 vs 12.6 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 15.1 vs 10.3 wk 52 · n 94 · Phase 3 · secondary NCT01668797
  • 18.9 vs 17.8 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 15.2 vs 11.4 wk 24 · n 94 · Phase 3 · secondary NCT01668797
  • 13 vs 9.4 wk 6 · n 133 · Phase 3 · secondary NCT01810380
  • 4.5 vs 7.6 0.25 mg · wk 6 · n 39 · Phase 2 · secondary NCT00905307
  • 11.4 vs 7.6 Low-dose · wk 6 · n 86 · Phase 2 · secondary NCT00905307
  • 10.7 vs 7.6 Mid-dose · wk 6 · n 84 · Phase 2 · secondary NCT00905307
  • 12.2 vs 7.6 High-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307

Relapse (% of patients)

Aripiprazole lauroxil (Aristada)
—Not reported
Brexpiprazole (Rexulti)
13.5% vs 38.5%−24.9 vs placebowk 52 · n 96NCT01668797
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Aripiprazole lauroxil (Aristada): 6 of 6 rows · Brexpiprazole (Rexulti): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAripiprazole lauroxil (Aristada)
Rows use multiple source trials
Brexpiprazole (Rexulti)
Rows use multiple source trials
CGI-S
absolute change · score
No placebo or comparator arm
-0.2 scorea,b,c,d
NCT02634320 · Phase 4 · registry result, not featured evidence
2 other source trials
-0.1 scoreHigh
NCT01895452 · Phase 3 · registry result, not featured evidence
-0.1 scoreLow
NCT01895452 · Phase 3 · registry result, not featured evidence
-0.48 score @ 52wke,a,b,c,d
NCT01397786 · Phase 3 · registry result, not featured evidence
show 2 more doses
-0.55 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
-0.97 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
PANSS Total
absolute change · score
No placebo or comparator arm
-0.9 scoreHighe,b,c,d
NCT01895452 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.7 scoreLow
NCT01895452 · Phase 3 · registry result, not featured evidence
-19 scoree,b,c,d
NCT03238326 · Phase 3
show 3 more doses
-18.44 score
NCT03238326 · Phase 3
-20.14 score
NCT03238326 · Phase 3
-19.76 score
NCT03238326 · Phase 3
Dropout rate
35.1%882 mgf
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
37.2%441 mg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
31.8%ALKS 9072, High
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
31.8%ALKS 9072, Low
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
31.4%
NCT02634320 · Phase 4 · registry result, not featured evidence
12.4%High
NCT01895452 · Phase 3 · registry result, not featured evidence
6.2%Low
NCT01895452 · Phase 3 · registry result, not featured evidence
30.6%2 mgg
NCT01393613 · Phase 3
show 45 more results
29.3%4 mg
NCT01393613 · Phase 3
32.5%1 mg
NCT01393613 · Phase 3
—2 mg
NCT01396421 · Phase 3
31.9%2 mg
NCT01396421 · Phase 3
32.8%4 mg
NCT01396421 · Phase 3
—4 mg
NCT01396421 · Phase 3
—0.25 mg
NCT01396421 · Phase 3
37.8%0.25 mg
NCT01396421 · Phase 3
0%De Novo (Conversion Period)
NCT03238326 · Phase 3
—De Novo (OLT Period)
NCT03238326 · Phase 3
—Prior & Current Brexpiprazole (OLT
NCT03238326 · Phase 3
—Prior Aripiprazole & Current Brexp
NCT03238326 · Phase 3
—Prior Placebo & Current Brexpipraz
NCT03238326 · Phase 3
—Prior and Current Brexpiprazole
NCT03238326 · Phase 3
2.7%
NCT03198078 · Phase 3
—
NCT01668797 · Phase 3
28.6%
NCT03526354 · Phase 4 · registry result, not featured evidence
15.8%2 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
47.4%4 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
12.3%De Novo
NCT01397786 · Phase 3 · registry result, not featured evidence
—De Novo (Phase A)
NCT01397786 · Phase 3 · registry result, not featured evidence
—De Novo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
0%Prior Brexpiprazole
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Brexpiprazole (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
51.9%
NCT01810783 · Phase 3 · registry result, not featured evidence
25.2%
NCT01810380 · Phase 3 · registry result, not featured evidence
49%
NCT02013622 · Phase 3 · registry result, not featured evidence
37.5%
NCT02054702 · Phase 3 · registry result, not featured evidence
29.6%2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
39.8%4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
37.4%1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
52.4%0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
—High-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
41.6%Low-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
41.1%Mid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
—Fasted Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
—Fed Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
0%4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
25%4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
0%1 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
14.9%4 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
27.4%12 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
—3mg
NCT01289080 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—882 mgf
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
—441 mg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
7.3%ALKS 9072, High
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
1.8%ALKS 9072, Low
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.9%
NCT02634320 · Phase 4 · registry result, not featured evidence
1.8%High
NCT01895452 · Phase 3 · registry result, not featured evidence
1.5%Low
NCT01895452 · Phase 3 · registry result, not featured evidence
5.9%2 mgg
NCT01393613 · Phase 3
show 45 more results
7.1%4 mg
NCT01393613 · Phase 3
9.2%1 mg
NCT01393613 · Phase 3
—2 mg
NCT01396421 · Phase 3
8.2%2 mg
NCT01396421 · Phase 3
9.4%4 mg
NCT01396421 · Phase 3
—4 mg
NCT01396421 · Phase 3
—0.25 mg
NCT01396421 · Phase 3
13.3%0.25 mg
NCT01396421 · Phase 3
—De Novo (Conversion Period)
NCT03238326 · Phase 3
—De Novo (OLT Period)
NCT03238326 · Phase 3
—Prior & Current Brexpiprazole (OLT
NCT03238326 · Phase 3
—Prior Aripiprazole & Current Brexp
NCT03238326 · Phase 3
—Prior Placebo & Current Brexpipraz
NCT03238326 · Phase 3
—Prior and Current Brexpiprazole
NCT03238326 · Phase 3
0%
NCT03198078 · Phase 3
—
NCT01668797 · Phase 3
—
NCT03526354 · Phase 4 · registry result, not featured evidence
—2 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
—4 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
3.5%De Novo
NCT01397786 · Phase 3 · registry result, not featured evidence
—De Novo (Phase A)
NCT01397786 · Phase 3 · registry result, not featured evidence
—De Novo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
0%Prior Brexpiprazole
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Brexpiprazole (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
15.2%
NCT01810783 · Phase 3 · registry result, not featured evidence
9.3%
NCT01810380 · Phase 3 · registry result, not featured evidence
6.1%
NCT02013622 · Phase 3 · registry result, not featured evidence
4.7%
NCT02054702 · Phase 3 · registry result, not featured evidence
10.4%2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
15.9%4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
16.5%1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
7.1%0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
—High-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
4.5%Low-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
5.6%Mid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
—Fasted Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
—Fed Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
—4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
—4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
—1 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
6.8%4 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
12.3%12 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
—3mg
NCT01289080 · Phase 1 · registry result, not featured evidence
Serious AEs
1.9%882 mgf
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
1.4%441 mg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
4.1%ALKS 9072, High
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
0%ALKS 9072, Low
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
9.8%
NCT02634320 · Phase 4 · registry result, not featured evidence
1.8%High
NCT01895452 · Phase 3 · registry result, not featured evidence
0%Low
NCT01895452 · Phase 3 · registry result, not featured evidence
2.2%2 mgg
NCT01393613 · Phase 3
show 45 more results
2.2%4 mg
NCT01393613 · Phase 3
2.5%1 mg
NCT01393613 · Phase 3
2.2%2 mg
NCT01396421 · Phase 3
—2 mg
NCT01396421 · Phase 3
—4 mg
NCT01396421 · Phase 3
1.1%4 mg
NCT01396421 · Phase 3
4.4%0.25 mg
NCT01396421 · Phase 3
—0.25 mg
NCT01396421 · Phase 3
0%De Novo (Conversion Period)
NCT03238326 · Phase 3
5%De Novo (OLT Period)
NCT03238326 · Phase 3
—Prior & Current Brexpiprazole (OLT
NCT03238326 · Phase 3
1.1%Prior Aripiprazole & Current Brexp
NCT03238326 · Phase 3
3.4%Prior Placebo & Current Brexpipraz
NCT03238326 · Phase 3
4.1%Prior and Current Brexpiprazole
NCT03238326 · Phase 3
0.9%
NCT03198078 · Phase 3
3.1%
NCT01668797 · Phase 3
0%
NCT03526354 · Phase 4 · registry result, not featured evidence
0%2 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
0%4 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
—De Novo
NCT01397786 · Phase 3 · registry result, not featured evidence
1.8%De Novo (Phase A)
NCT01397786 · Phase 3 · registry result, not featured evidence
11.2%De Novo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Brexpiprazole
NCT01397786 · Phase 3 · registry result, not featured evidence
14.9%Prior Brexpiprazole (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo
NCT01397786 · Phase 3 · registry result, not featured evidence
8.9%Prior Placebo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
14.8%
NCT01810783 · Phase 3 · registry result, not featured evidence
4.7%
NCT01810380 · Phase 3 · registry result, not featured evidence
0%
NCT02013622 · Phase 3 · registry result, not featured evidence
4.7%
NCT02054702 · Phase 3 · registry result, not featured evidence
4.4%2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
4.4%4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
7%1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
0%0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
4.3%High-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
3.4%Low-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
5.6%Mid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
0%Fasted Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
1.8%Fed Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
0%4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
0%4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
0%1 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
1.4%4 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
0%12 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
0%3mg
NCT01289080 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
882 mgf
insomnia 12% (placebo 11.6%)
akathisia 11.1% (placebo 4.3%)
headache 8.7% (placebo 8.2%)
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
441 mg
akathisia 11.6% (placebo 4.3%)
insomnia 9.7% (placebo 11.6%)
headache 8.2% (placebo 8.2%)
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
insomnia 10.1%
weight increased 4.6%
headache 3%
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
headache 6.4%
weight increased 6.4%
insomnia 2.7%
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
anxiety 5.9%
NCT02634320 · Phase 4 · registry result, not featured evidence
High
insomnia 7.1%
nasopharyngitis 4%
diarrhoea 3.1%
NCT01895452 · Phase 3 · registry result, not featured evidence
Low
diarrhoea 6.2%
nasopharyngitis 6.2%
toothache 6.2%
NCT01895452 · Phase 3 · registry result, not featured evidence
2 mgg
insomnia 13.4% (placebo 14.7%)
headache 10.8% (placebo 14.7%)
agitation 8.6% (placebo 7.1%)
NCT01393613 · Phase 3
show 38 more results
4 mg
insomnia 15.2% (placebo 14.7%)
headache 10.3% (placebo 14.7%)
agitation 7.1% (placebo 7.1%)
NCT01393613 · Phase 3
1 mg
insomnia 12.5% (placebo 14.7%)
agitation 8.3% (placebo 7.1%)
headache 7.5% (placebo 14.7%)
NCT01393613 · Phase 3
2 mg
headache 9.3% (placebo 8.2%)
insomnia 8.8% (placebo 9.8%)
agitation 6% (placebo 10.3%)
NCT01396421 · Phase 3
4 mg
headache 12.2% (placebo 8.2%)
insomnia 8.3% (placebo 9.8%)
agitation 7.2% (placebo 10.3%)
NCT01396421 · Phase 3
0.25 mg
headache 10% (placebo 8.2%)
insomnia 8.9% (placebo 9.8%)
schizophrenia 6.7% (placebo 9.8%)
NCT01396421 · Phase 3
irritability 14.3%
somnolence 14.3%
akathisia 7.1%
NCT03238326 · Phase 3
somnolence 30%
weight increased 20%
coronavirus test positive 10%
NCT03238326 · Phase 3
weight increased 13.5%
headache 10.1%
somnolence 7.9%
NCT03238326 · Phase 3
headache 12.6%
somnolence 10.3%
weight increased 10.3%
NCT03238326 · Phase 3
headache 10.2%
nasopharyngitis 9.2%
somnolence 9.2%
NCT03238326 · Phase 3
headache 6.4% (placebo 4.8%)
nausea 6.4% (placebo 3.8%)
somnolence 4.5% (placebo 4.8%)
NCT03198078 · Phase 3
agitation 0% (placebo 0%)
akathisia 0% (placebo 0%)
headache 0% (placebo 0%)
NCT01668797 · Phase 3
fatigure/tiredness 14.3%
nausea 14.3%
cold-like symptoms 9.5%
NCT03526354 · Phase 4 · registry result, not featured evidence
2 mg
headache 15.8%
insomnia 10.5%
irritability 10.5%
NCT02194933 · Phase 3 · registry result, not featured evidence
4 mg
agitation 10.5%
anxiety 10.5%
back pain 10.5%
NCT02194933 · Phase 3 · registry result, not featured evidence
agitation 0%
akathisia 0%
headache 0%
NCT01397786 · Phase 3 · registry result, not featured evidence
insomnia 12.5%
headache 9.4%
agitation 9%
NCT01397786 · Phase 3 · registry result, not featured evidence
insomnia 8.4%
weight increased 7.8%
headache 6.9%
NCT01397786 · Phase 3 · registry result, not featured evidence
insomnia 8.4%
weight increased 7.4%
akathisia 6.9%
NCT01397786 · Phase 3 · registry result, not featured evidence
weight increased 10.5%
headache 8.6%
insomnia 8.1%
NCT01810783 · Phase 3 · registry result, not featured evidence
insomnia 8.7% (placebo 6.2%)
akathisia 6% (placebo 2.5%)
headache 5.3% (placebo 6.8%)
NCT01810380 · Phase 3 · registry result, not featured evidence
insomnia 14.3%
somnolence 8.2%
nausea 6.1%
NCT02013622 · Phase 3 · registry result, not featured evidence
akathisia 9.4%
weight increased 9.4%
dry mouth 7.8%
NCT02054702 · Phase 3 · registry result, not featured evidence
2 mg
schizophrenia 11.4% (placebo 24.1%)
headache 7.9% (placebo 4.3%)
constipation 7% (placebo 7.8%)
NCT01451164 · Phase 2/3 · registry result, not featured evidence
4 mg
schizophrenia 20.4% (placebo 24.1%)
nasopharyngitis 8.8% (placebo 9.5%)
vomiting 7.1% (placebo 3.4%)
NCT01451164 · Phase 2/3 · registry result, not featured evidence
1 mg
schizophrenia 17.4% (placebo 24.1%)
nasopharyngitis 10.4% (placebo 9.5%)
constipation 7% (placebo 7.8%)
NCT01451164 · Phase 2/3 · registry result, not featured evidence
0.25 mg
headache 14.3% (placebo 10.5%)
anxiety 11.9% (placebo 10.5%)
agitation 9.5% (placebo 4.2%)
NCT00905307 · Phase 2 · registry result, not featured evidence
High-dose
akathisia 15.1% (placebo 4.2%)
anxiety 10.8% (placebo 10.5%)
insomnia 9.7% (placebo 16.8%)
NCT00905307 · Phase 2 · registry result, not featured evidence
Low-dose
insomnia 13.5% (placebo 16.8%)
headache 9% (placebo 10.5%)
anxiety 7.9% (placebo 10.5%)
NCT00905307 · Phase 2 · registry result, not featured evidence
Mid-dose
headache 14.4% (placebo 10.5%)
insomnia 10% (placebo 16.8%)
weight increased 10% (placebo 3.2%)
NCT00905307 · Phase 2 · registry result, not featured evidence
nausea 9.6%
somnolence 9.6%
diarrhoea 5.8%
NCT06036108 · Phase 1 · registry result, not featured evidence
vomiting 20%
nausea 12.7%
somnolence 12.7%
NCT06036108 · Phase 1 · registry result, not featured evidence
4 mg
abdominal pain 25%
akathisia 25%
blepharospasm 25%
NCT01854944 · Phase 1 · registry result, not featured evidence
4 mg
akathisia 25%
dental carries 25%
dyspepsia 25%
NCT01854944 · Phase 1 · registry result, not featured evidence
1 mg
abdominal discomfort 50%
agitation 25%
abdominal pain 0%
NCT01854944 · Phase 1 · registry result, not featured evidence
4 mg
nausea 10% (placebo 5.9%)
application site dermatitis 8.6% (placebo 5.9%)
dizziness 8.6% (placebo 1.5%)
NCT01423916 · Phase 1 · registry result, not featured evidence
12 mg
dizziness 11.9% (placebo 1.5%)
akathisia 7.5% (placebo 1.5%)
extrapyramidal disorder 7.5% (placebo 1.5%)
NCT01423916 · Phase 1 · registry result, not featured evidence
3mg
somnolence 15.8%
headache 10.5%
orthostatic hypotension 10.5%
NCT01289080 · Phase 1 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 4.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for 3 of these studies.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aripiprazole lauroxil (Aristada)

PANSS Total -10 vs -19.1 placebo score @ 52wk441-441 mg
absolute change · score
Total Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-8.3 vs -19.1 placebo score @ 52wk882-882 mg
Total Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-5.9 vs -19.1 placebo score @ 52wk
Total Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Positive Subscale -3.4 vs -5.8 placebo score @ 52wk441-441 mg
absolute change · score
Positive Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-2.3 vs -5.8 placebo score @ 52wk882-882 mg
Positive Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.8 vs -5.8 placebo score @ 52wk
Positive Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Negative Subscale -1.5 vs -4.1 placebo score @ 52wk441-441 mg
absolute change · score
Negative Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-2.1 vs -4.1 placebo score @ 52wk882-882 mg
Negative Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.2 vs -4.1 placebo score @ 52wk
Negative Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS General Psychopathology -5.1 vs -9.2 placebo score @ 52wk441-441 mg
absolute change · score
General Psychopathology Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-4 vs -9.2 placebo score @ 52wk882-882 mg
General Psychopathology Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-2.9 vs -9.2 placebo score @ 52wk
General Psychopathology Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
BPRS Total -2.7 score
absolute change · score
No placebo or comparator arm
NCT02634320 · Phase 4 · registry result, not featured evidence
QLS Total 0.4 score
absolute change · score
No placebo or comparator arm
NCT02634320 · Phase 4 · registry result, not featured evidence

Brexpiprazole (Rexulti)

PSP 6.85 vs 5.8 placebo score @ 3wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 17 more results
10.52 vs 8.52 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
13.15 vs 10.26 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
7.12 vs 5.8 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
13.11 vs 8.52 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
12.72 vs 10.26 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
6.97 vs 5.8 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
11.73 vs 8.52 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
11.84 vs 10.26 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
4.54 vs 7.56 placebo score @ 6wk0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
18.85 vs 17.84 placebo score @ 24wk
NCT01668797 · Phase 3
18.63 vs 12.55 placebo score @ 52wk
NCT01668797 · Phase 3
15.2 vs 11.41 placebo score @ 24wk
NCT01668797 · Phase 3
15.06 vs 10.31 placebo score @ 52wk
NCT01668797 · Phase 3
13 vs 9.4 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
11.36 vs 7.56 placebo score @ 6wkLow-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
10.67 vs 7.56 placebo score @ 6wkMid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
12.17 vs 7.56 placebo score @ 6wkHigh-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
PANSS Positive -1.43 vs -1.25 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 35 more results
-2.76 vs -2.56 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-3.56 vs -3.34 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-4.35 vs -3.93 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-4.68 vs -4.33 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-5.42 vs -4.95 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-1.31 vs -1.09 placebo score @ 1wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.31 vs -2.25 placebo score @ 2wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.21 vs -2.57 placebo score @ 3wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.69 vs -2.9 placebo score @ 4wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-4.05 vs -3.26 placebo score @ 5wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-4.32 vs -3.69 placebo score @ 6wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.8 vs -1.25 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-2.93 vs -2.56 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-4.43 vs -3.34 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-5.16 vs -3.93 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-6.04 vs -4.33 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-6.65 vs -4.95 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-0.7 vs -1.09 placebo score @ 1wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.61 vs -2.25 placebo score @ 2wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.71 vs -2.57 placebo score @ 3wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.09 vs -2.9 placebo score @ 4wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.89 vs -3.26 placebo score @ 5wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.15 vs -3.69 placebo score @ 6wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-0.93 vs -1.25 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-2.54 vs -2.56 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-3.94 vs -3.34 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-4.83 vs -3.93 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-4.8 vs -4.33 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-5.63 vs -4.95 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-0.96 vs -1.09 placebo score @ 1wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.72 vs -2.25 placebo score @ 2wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.07 vs -2.57 placebo score @ 3wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.39 vs -2.9 placebo score @ 4wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.19 vs -3.26 placebo score @ 5wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.22 vs -3.69 placebo score @ 6wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
PANSS Negative -0.52 vs -0.4 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 35 more results
-1.31 vs -0.79 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-1.8 vs -1.18 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-2.09 vs -1.67 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-2.5 vs -1.74 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-2.91 vs -2.14 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-0.83 vs -0.59 placebo score @ 1wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.46 vs -0.72 placebo score @ 2wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.41 vs -1.14 placebo score @ 3wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.9 vs -0.81 placebo score @ 4wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.24 vs -0.85 placebo score @ 5wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.48 vs -1.2 placebo score @ 6wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-0.88 vs -0.4 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.42 vs -0.79 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-2.15 vs -1.18 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-2.69 vs -1.67 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-2.82 vs -1.74 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-3.36 vs -2.14 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-0.71 vs -0.59 placebo score @ 1wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.76 vs -0.72 placebo score @ 2wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.27 vs -1.14 placebo score @ 3wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.94 vs -0.81 placebo score @ 4wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.19 vs -0.85 placebo score @ 5wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.24 vs -1.2 placebo score @ 6wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-0.31 vs -0.4 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-1.27 vs -0.79 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-2.06 vs -1.18 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-2.56 vs -1.67 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-2.71 vs -1.74 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-2.92 vs -2.14 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-0.54 vs -0.59 placebo score @ 1wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.08 vs -0.72 placebo score @ 2wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.64 vs -1.14 placebo score @ 3wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.36 vs -0.81 placebo score @ 4wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.31 vs -0.85 placebo score @ 5wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.34 vs -1.2 placebo score @ 6wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
CGI-I 3.17 vs 3.48 placebo score @ 6wk2 mg
absolute value · score
NCT01393613 · Phase 3
show 34 more results
2.94 vs 3.48 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
3.84 vs 3.92 placebo score @ 1wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.68 vs 3.88 placebo score @ 2wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.53 vs 3.92 placebo score @ 3wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.51 vs 3.9 placebo score @ 4wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.42 vs 3.86 placebo score @ 5wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.49 vs 3.83 placebo score @ 6wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
2.95 vs 3.48 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
2.94 vs 3.48 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
4.01 vs 3.92 placebo score @ 1wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.79 vs 3.88 placebo score @ 2wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.77 vs 3.92 placebo score @ 3wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.81 vs 3.9 placebo score @ 4wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.76 vs 3.86 placebo score @ 5wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.78 vs 3.83 placebo score @ 6wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.2 vs 3.48 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
3.87 vs 3.92 placebo score @ 1wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.87 vs 3.88 placebo score @ 2wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.89 vs 3.92 placebo score @ 3wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.83 vs 3.9 placebo score @ 4wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.92 vs 3.86 placebo score @ 5wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.9 vs 3.83 placebo score @ 6wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
3.37 vs 3.48 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
3.66 vs 3.34 placebo score @ 6wk0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
2.86 vs 3.17 placebo score @ 6wk
NCT03198078 · Phase 3
3.68 vs 4 placebo score @ 6wk
NCT01668797 · Phase 3
3.66 vs 4.1 placebo score @ 12wk
NCT01668797 · Phase 3
3.67 vs 4.3 placebo score @ 24wk
NCT01668797 · Phase 3
3.71 vs 4.39 placebo score @ 36wk
NCT01668797 · Phase 3
3.77 vs 4.4 placebo score @ 52wk
NCT01668797 · Phase 3
2.7 vs 3 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
3.08 vs 3.34 placebo score @ 6wkLow-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
3.17 vs 3.34 placebo score @ 6wkMid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
3.04 vs 3.34 placebo score @ 6wkHigh-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
PANSS 38.5% (n=179) vs 31.7% (n=180) placebo @ 6wk2 mg
responder rate · % of participants
NCT01393613 · Phase 3
show 8 more results
49.7% (n=181) vs 31.7% (n=180) placebo @ 6wk4 mg
NCT01393613 · Phase 3
43.6% (n=117) vs 31.7% (n=180) placebo @ 6wk1 mg
NCT01393613 · Phase 3
40.5% (n=42) vs 49.5% (n=95) placebo @ 6wk0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
43.64% (n=110) vs 28.16% (n=103) placebo @ 6wk
NCT03198078 · Phase 3
48.7% (n=150) vs 32.1% (n=159) placebo @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
57.3% (n=89) vs 49.5% (n=95) placebo @ 6wkLow-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
46.7% (n=90) vs 49.5% (n=95) placebo @ 6wkMid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
51.6% (n=93) vs 49.5% (n=95) placebo @ 6wkHigh-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
PANSS-EC -0.46 vs -0.48 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-1.31 vs -0.62 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-1.31 vs -0.82 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-1.52 vs -1.12 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-1.48 vs -0.97 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-1.9 vs -1.47 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-2.87 vs -1.64 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-1.01 vs -0.48 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.21 vs -0.62 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-1.81 vs -0.82 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-2.12 vs -1.12 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-2.27 vs -0.97 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-2.86 vs -1.47 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-2.75 vs -1.64 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-0.35 vs -0.48 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-0.76 vs -0.62 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-1.21 vs -0.82 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-1.58 vs -1.12 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-1.16 vs -0.97 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-1.94 vs -1.47 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-1.99 vs -1.64 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
0.32 vs 0.74 placebo score @ 6wk
NCT01668797 · Phase 3
0.5 vs 1.16 placebo score @ 12wk
NCT01668797 · Phase 3
-0.06 vs 0.45 placebo score @ 24wk
NCT01668797 · Phase 3
0.1 vs 1.25 placebo score @ 36wk
NCT01668797 · Phase 3
-0.04 vs 1 placebo score @ 52wk
NCT01668797 · Phase 3
0.38 vs 0.81 placebo score @ 6wk
NCT01668797 · Phase 3
0.73 vs 1.36 placebo score @ 12wk
NCT01668797 · Phase 3
0.78 vs 1.86 placebo score @ 24wk
NCT01668797 · Phase 3
0.89 vs 2.23 placebo score @ 36wk
NCT01668797 · Phase 3
0.82 vs 2.35 placebo score @ 52wk
NCT01668797 · Phase 3
-3.3 vs -2.5 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Positive -1.77 vs -1.3 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-3.1 vs -3.03 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-4.09 vs -3.78 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-4.93 vs -4.67 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-5.35 vs -5.47 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-6.26 vs -5.91 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-7.37 vs -4.89 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-1.75 vs -1.3 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-3.03 vs -3.03 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-4.39 vs -3.78 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-5.48 vs -4.67 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-6.41 vs -5.47 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-7.05 vs -5.91 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-7.23 vs -4.89 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-1.44 vs -1.3 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-2.97 vs -3.03 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-4.48 vs -3.78 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-5.42 vs -4.67 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-5.86 vs -5.47 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-6.56 vs -5.91 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-5.78 vs -4.89 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
-0.1 vs 1.24 placebo score @ 6wk
NCT01668797 · Phase 3
-0.18 vs 1.83 placebo score @ 12wk
NCT01668797 · Phase 3
-0.82 vs 0.77 placebo score @ 24wk
NCT01668797 · Phase 3
-1.35 vs 0.93 placebo score @ 36wk
NCT01668797 · Phase 3
-1.62 vs 1.78 placebo score @ 52wk
NCT01668797 · Phase 3
0.05 vs 1.13 placebo score @ 6wk
NCT01668797 · Phase 3
0.1 vs 2.03 placebo score @ 12wk
NCT01668797 · Phase 3
0.25 vs 3.08 placebo score @ 24wk
NCT01668797 · Phase 3
0.6 vs 3.69 placebo score @ 36wk
NCT01668797 · Phase 3
0.58 vs 4.02 placebo score @ 52wk
NCT01668797 · Phase 3
-7.1 vs -5.7 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Negative -0.85 vs -0.66 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-1.86 vs -1.38 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-2.3 vs -1.83 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-2.63 vs -2.16 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-3.13 vs -2.24 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-3.53 vs -2.55 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-4.48 vs -2.8 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-1.12 vs -0.66 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.72 vs -1.38 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-2.64 vs -1.83 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-3.17 vs -2.16 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-3.21 vs -2.24 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-3.84 vs -2.55 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-4.1 vs -2.8 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-0.7 vs -0.66 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-1.71 vs -1.38 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-2.55 vs -1.83 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-3.21 vs -2.16 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-3.35 vs -2.24 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-3.55 vs -2.55 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-3.66 vs -2.8 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
0.02 vs 0.68 placebo score @ 6wk
NCT01668797 · Phase 3
-0.01 vs 0.8 placebo score @ 12wk
NCT01668797 · Phase 3
-0.71 vs 0.46 placebo score @ 24wk
NCT01668797 · Phase 3
-0.8 vs 0.7 placebo score @ 36wk
NCT01668797 · Phase 3
1.37 vs 1.06 placebo score @ 52wk
NCT01668797 · Phase 3
-0.24 vs 0.61 placebo score @ 6wk
NCT01668797 · Phase 3
-0.15 vs 1.09 placebo score @ 12wk
NCT01668797 · Phase 3
-0.09 vs 1.5 placebo score @ 24wk
NCT01668797 · Phase 3
-0.07 vs 1.56 placebo score @ 36wk
NCT01668797 · Phase 3
0.34 vs 1.57 placebo score @ 52wk
NCT01668797 · Phase 3
-4.3 vs -3.6 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Disorganized Thought -0.46 vs -0.42 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 28 more results
-1.15 vs -0.71 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-1.71 vs -1.35 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-2.27 vs -1.77 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-2.55 vs -2.01 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-2.94 vs -2.59 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-0.78 vs -0.42 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.37 vs -0.71 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-2.32 vs -1.35 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-2.83 vs -1.77 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-3.42 vs -2.01 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-3.98 vs -2.59 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-0.4 vs -0.42 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-1.42 vs -0.71 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-2.35 vs -1.35 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-2.56 vs -1.77 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-2.95 vs -2.01 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-3.46 vs -2.59 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-0.18 vs 0.32 placebo score @ 6wk
NCT01668797 · Phase 3
-0.44 vs 0.69 placebo score @ 12wk
NCT01668797 · Phase 3
-1.26 vs 0.27 placebo score @ 24wk
NCT01668797 · Phase 3
-1.31 vs 0.17 placebo score @ 36wk
NCT01668797 · Phase 3
-0.37 vs -0.3 placebo score @ 52wk
NCT01668797 · Phase 3
-0.32 vs 0.33 placebo score @ 6wk
NCT01668797 · Phase 3
-0.19 vs 1.19 placebo score @ 12wk
NCT01668797 · Phase 3
-0.29 vs 1.76 placebo score @ 24wk
NCT01668797 · Phase 3
0 vs 1.95 placebo score @ 36wk
NCT01668797 · Phase 3
0.29 vs 1.97 placebo score @ 52wk
NCT01668797 · Phase 3
-4 vs -3.2 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Uncontrolled Hostility/Excitement -0.1 vs -0.21 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-0.65 vs -0.13 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-0.61 vs -0.19 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-0.74 vs -0.39 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-0.6 vs -0.22 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-0.81 vs -0.64 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-1.91 vs -0.82 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-0.63 vs -0.21 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-0.68 vs -0.13 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-1.16 vs -0.19 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-1.31 vs -0.39 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-1.5 vs -0.22 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-1.89 vs -0.64 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-1.9 vs -0.82 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
0.03 vs -0.21 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-0.15 vs -0.13 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-0.46 vs -0.19 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-0.74 vs -0.39 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-0.34 vs -0.22 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-0.9 vs -0.64 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-1.15 vs -0.82 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
0.19 vs 0.55 placebo score @ 6wk
NCT01668797 · Phase 3
0.33 vs 0.82 placebo score @ 12wk
NCT01668797 · Phase 3
-0.26 vs 0.81 placebo score @ 24wk
NCT01668797 · Phase 3
-0.13 vs 0.94 placebo score @ 36wk
NCT01668797 · Phase 3
-0.2 vs 0.94 placebo score @ 52wk
NCT01668797 · Phase 3
0.32 vs 0.65 placebo score @ 6wk
NCT01668797 · Phase 3
0.52 vs 0.94 placebo score @ 12wk
NCT01668797 · Phase 3
0.5 vs 1.31 placebo score @ 24wk
NCT01668797 · Phase 3
0.57 vs 1.63 placebo score @ 36wk
NCT01668797 · Phase 3
0.49 vs 1.75 placebo score @ 52wk
NCT01668797 · Phase 3
-2.5 vs -1.8 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Anxiety Depression -1.1 vs -0.96 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-1.91 vs -1.47 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-2.1 vs -1.97 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-2.7 vs -2.6 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-2.87 vs -2.69 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-3.62 vs -2.93 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-3.7 vs -3.05 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-1.26 vs -0.96 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.6 vs -1.47 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-2.24 vs -1.97 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-2.93 vs -2.6 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-3.09 vs -2.69 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-3.78 vs -2.93 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-3.4 vs -3.05 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-1.18 vs -0.96 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-1.86 vs -1.47 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-2.43 vs -1.97 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-2.85 vs -2.6 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-2.93 vs -2.69 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-3.57 vs -2.93 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-3.27 vs -3.05 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
0.19 vs 0.66 placebo score @ 6wk
NCT01668797 · Phase 3
0.54 vs 0.78 placebo score @ 12wk
NCT01668797 · Phase 3
0.61 vs 0.58 placebo score @ 24wk
NCT01668797 · Phase 3
0.46 vs 0.71 placebo score @ 36wk
NCT01668797 · Phase 3
0.04 vs 0.28 placebo score @ 52wk
NCT01668797 · Phase 3
0.19 vs 0.85 placebo score @ 6wk
NCT01668797 · Phase 3
0.86 vs 1.41 placebo score @ 12wk
NCT01668797 · Phase 3
1.07 vs 1.64 placebo score @ 24wk
NCT01668797 · Phase 3
1.09 vs 1.79 placebo score @ 36wk
NCT01668797 · Phase 3
1.17 vs 1.88 placebo score @ 52wk
NCT01668797 · Phase 3
-3.2 vs -2.9 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Positive Subscale -6.57 vs -4.35 placebo score @ 6wk2 mg
absolute change · score
NCT01396421 · Phase 3
show 17 more results
-6.78 vs -4.35 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-5.46 vs -4.35 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
-3.22 vs -4.82 placebo score @ 6wk0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
0.17 vs 1.28 placebo score @ 6wk
NCT01668797 · Phase 3
-0.06 vs 1.81 placebo score @ 12wk
NCT01668797 · Phase 3
-0.84 vs 0.72 placebo score @ 24wk
NCT01668797 · Phase 3
-0.97 vs 0.91 placebo score @ 36wk
NCT01668797 · Phase 3
-1.21 vs 1.5 placebo score @ 52wk
NCT01668797 · Phase 3
0.3 vs 1.25 placebo score @ 6wk
NCT01668797 · Phase 3
0.38 vs 2.24 placebo score @ 12wk
NCT01668797 · Phase 3
0.49 vs 3.23 placebo score @ 24wk
NCT01668797 · Phase 3
0.97 vs 3.91 placebo score @ 36wk
NCT01668797 · Phase 3
0.99 vs 4.17 placebo score @ 52wk
NCT01668797 · Phase 3
-7 vs -5.4 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
-5.97 vs -4.82 placebo score @ 6wkLow-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
-4.94 vs -4.82 placebo score @ 6wkMid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
-5.98 vs -4.82 placebo score @ 6wkHigh-dose
NCT00905307 · Phase 2 · registry result, not featured evidence

+ 56 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole lauroxil (Aristada)'s landscape · Brexpiprazole (Rexulti)'s landscape